by R. Matthew Chico, Enesia Banda Chaponda, Cono Ariti et al.
Clin Infect Dis. – Published: 02 March 2017
The authors conducted a prospective cohort study in Zambia among pregnant women who received intermittent preventive treatment using sulfadoxine-pyrimethamine (IPTp-SP). They analyzed data from these women, relating the incidence of malaria infection and curable sexually transmitted and reproductive tract infections (STIs/RTIs), maternal exposure to IPTp-SP during the antenatal period (0–1 doses vs ≥2 doses and, separately, 2 doses vs ≥3 doses), and the resulting incidence of the following 4 adverse birth outcomes: stillbirth, low birth weight (LBW), preterm delivery, and intrauterine growth retardation (IUGR). They conclude that IPTp-SP appears to protect against malaria, STIs/RTIs, and other unspecified causes of adverse birth outcome.